| Model Number |
04.043.235S |
| Medical Device Problem Code |
Adverse Event Without Identified Device or Use Problem (2993)
|
| Health Effect - Clinical Codes |
Hematoma (1884); Seroma (2069)
|
| Date of Event |
01/01/2023
|
|
Type of Reportable Event
|
Serious Injury
|
|
Event or Problem Description
|
|
A new ae has been reported for subject (b)(6).Adverse event term: left thigh hematoma.Site awareness date: (b)(6) 2023.Start date: (b)(6) 2023.Type of event: local/fracture site.Side: left.Device: rfna.Serious: yes.This report is for a tibial nail-advanced / 10mm 345mm / sterile.This is report 4 of 12 for (b)(4).
|
| |
|
Additional Manufacturer Narrative
|
|
Depuy synthes is submitting this report pursuant to the provisions of 21 cfr, part 803.This report may be based on information which depuy synthes has not been able to investigate or verify prior to the required reporting date.This report does not reflect a conclusion by fda, depuy synthes or its employees that the report constitutes an admission that the device, depuy synthes, or its employees caused or contributed to the potential event described in this report.Additional procode: jds.Complainant part is not expected to be returned for manufacturer review/investigation.Initial reporter is a synthes employee.The investigation could not be completed; no conclusion could be drawn, as no product was received.Based on the information available, it has been determined that no corrective and/or preventative action is proposed.This complaint will be accounted for and monitored via post market surveillance activities.If additional information is made available, the investigation will be updated as applicable.Device was used for treatment, not diagnosis.If information is obtained that was not available for the initial medwatch, a follow-up medwatch will be filed as appropriate.
|
| |
|
Event or Problem Description
|
|
The following adverse event was reported for subject (b)(4): it was reported that the patient underwent surgery to implant the devices on (b)(6) 2022 after sustaining a high-energy trauma injury.On (b)(6) 2023, it was noted that the patient had developed a hematoma at the fracture site on the left thigh.The patient required in-patient hospitalization or prolongation of existing hospitalization, and was treated with injected medication and other non-surgical treatments.The adverse event was considered resolved as of (b)(6) 2023.
|
| |
|
Additional Manufacturer Narrative
|
|
Depuy synthes is submitting this report pursuant to the provisions of 21 cfr, part 803.This report may be based on information which depuy synthes has not been able to investigate or verify prior to the required reporting date.This report does not reflect a conclusion by fda, depuy synthes or its employees that the report constitutes an admission that the device, depuy synthes, or its employees caused or contributed to the potential event described in this report.Product was not returned.Based on the information available, it has been determined that no corrective and preventative action is proposed.This complaint will be accounted for and monitored via post market surveillance activities.If additional information is made available, the investigation will be updated as applicable device history product code: 04.043.235s-us, lot number: 518p008, manufacturing site: jabil bettlach, release to warehouse date:15/12/2021, expiry date:30/11/2031.A manufacturing record evaluation was performed for the finished device lot and no non-conformance was identified.Device was used for treatment, not diagnosis.If information is obtained that was not available for the initial medwatch, a follow-up medwatch will be filed as appropriate.
|
| |
|
Search Alerts/Recalls
|